SCHEMBL715055

SCHEMBL715055

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@H](O)CNCc1cccc(C(F)(F)F)c1

nearest known ligand 0.69

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 18/20 0.69
BCHE P06276 2/20 0.69
CTSD P07339 13/20 0.60
BACE2 Q9Y5Z0 12/20 0.60
ATM Q13315 1/20 0.56
KLK5 Q9Y337 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL716159 1.00 BACE1 (0.69) BACE1BCHECTSDBACE2ATM
SCHEMBL8066182 0.94 BACE1 (0.61) BACE1BCHECTSDBACE2ATM
SCHEMBL30318988 0.92 BACE1 (0.72) BACE1BCHECTSDBACE2ATM
SCHEMBL13306181 0.92 BACE1 (0.72) BACE1BCHECTSDBACE2
SCHEMBL13306696 0.92 BACE1 (0.72) BACE1BCHECTSDBACE2
SCHEMBL8075124 0.92 BACE1 (0.72) BACE1BCHECTSDBACE2
SCHEMBL13033155 0.91 BACE1 (0.62) BACE1BCHECTSDBACE2ATM
SCHEMBL5386844 0.90 BACE1 (0.57) BACE1BCHECTSDBACE2ATM
SCHEMBL5386841 0.90 BACE1 (0.57) BACE1BCHECTSDBACE2ATM
SCHEMBL4809494 0.88 ATM (0.72) BACE1BCHEATMKLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4153561-B1 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS UNIV JAGIELLONSKI (PL) 2026-04-29 EP disclosed
US-12492163-B2 9H-fluorene derivatives or their pharmaceutically acceptable salts UNIWERSYTET JAGIELLONSKI (PL) 2025-12-09 US disclosed
US-20230117233-A1 NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS UNIWERSYTET JAGIELLONSKI (PL) 2023-04-20 US disclosed
EP-4153561-A2 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS UNIWERSYTET JAGIELLONSKI (PL) 2023-03-29 EP disclosed
EP-2185525-B1 PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2016-12-14 EP disclosed
US-9102628-B2 Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics SANOFI (FR) 2015-08-11 US disclosed
US-8299267-B2 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating COMENTIS, INC. (US) 2012-10-30 US disclosed
US-8299267-B2 (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating COMENTIS, INC. (US) 2012-10-30 US disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
US-20100286170-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC 2010-11-11 US disclosed
US-20100286170-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING COMENTIS, INC 2010-11-11 US disclosed
US-20100160377-A1 DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS SANOFI-AVENTIS (FR) 2010-06-24 US disclosed
WO-2009027601-A2 PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-03-05 WO disclosed
WO-2006103088-A1 NOVEL HYDROXYETHYLAMINE AND KETONE COMPOUNDS HAVING ASP2 INHIBITORY ACTIVITY GLAXO GROUP LIMITED (GB) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117233-A1 NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS BACE1, BACE2, APP BACE1 1/4885BCHE 4/4885CTSD 37/4885
US-20100160377-A1 DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS CYP3A5, ADH5, AVPR2 BACE1 3223/4885BCHE 3099/4885CTSD 2356/4885
US-12492163-B2 9H-fluorene derivatives or their pharmaceutically acceptable salts BACE1, BACE2, APP BACE1 1/4885BCHE 5/4885CTSD 37/4885
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 BACE1 2/4885BCHE 22/4885CTSD 138/4885
US-20100286170-A1 (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING BACE1, BACE2, PSEN1 BACE1 1/4885BCHE 11/4885CTSD 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.